Pulse Biosciences, Inc. (PLSE)
| Market Cap | 1.48B |
| Revenue (ttm) | 350,000 |
| Net Income (ttm) | -72.78M |
| Shares Out | 67.99M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 270,840 |
| Open | 22.70 |
| Previous Close | 22.65 |
| Day's Range | 21.31 - 23.02 |
| 52-Week Range | 12.56 - 26.30 |
| Beta | 1.69 |
| Analysts | Buy |
| Price Target | 22.00 (+0.78%) |
| Earnings Date | May 7, 2026 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price target is $22.0.
News
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, t...
Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its ...
Pulse Biosciences to Host Analyst Event on April 25, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to h...
Pulse Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing proprietary nanosecond pulsed field ablation technology, targeting rapid, efficient AFib treatment with a single catheter system. Strong clinical data, robust IP, and a solid financial position support accelerated IDE enrollment and expansion into new indications, with pivotal regulatory milestones expected by early 2028.
Pulse Biosciences Strengthens Executive Leadership Team
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the streng...
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment...
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to pr...
Pulse Biosciences Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Exceptional clinical results with nanosecond PFA technology are driving strong investigator interest and rapid IDE study enrollment, with enhanced mapping integration and a focus on strategic partnerships. Resource allocation is shifting toward the EP program, with increased R&D spending expected in 2026.
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strat...
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) e...
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) e...
Pulse Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted major advances in nanosecond pulsed field ablation, with clinical data showing unprecedented success rates in atrial fibrillation treatment and rapid, efficient workflows. The company is well-funded, expanding its pipeline into cardiac surgery and oncology, and expects to complete key clinical trial enrollments in 2026.
Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) e...
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
Pulse Biosciences Earnings Call Transcript: Q4 2025
Advanced nsPFA platform achieved strong clinical and commercial milestones in 2025, with robust cardiac and soft tissue ablation results, increased Q4 revenue, and a solid cash position. Pivotal trials and CE Mark submissions are planned for 2026, with FDA clearances expected in 2027.
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
What's Going With Pulse Biosciences Stock On Monday?
Pulse Biosciences Inc. (NASDAQ: PLSE) stock is trading higher on continued strength after the company on Friday shared clinical data from its nPulse Cardiac Catheter first-in-human feasibility study.
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or n...
Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or n...
Pulse Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Pulse Biosciences highlighted rapid progress in clinical and commercial development of its proprietary nsPFA technology, targeting large markets in electrophysiology, cardiac surgery, and thyroid ablation. IDE approvals, strong IP, and early commercialization position the company for significant milestones in 2026.
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or n...
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or n...